Clinical Usefulness of Therapeutic Drug Monitoring of Colistin in Patients Treated With Colistin.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03007290

Enrollment

Registered

2017-01-02

Start date

2016-01-31

Completion date

2017-12-31

Last updated

2018-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multidrug-resistant Gram-negative Bacteria Infection

Brief summary

Clinical usefulness of therapeutic drug monitoring of colistin in patients treated with colistin

Interventions

OTHERTherapeutic drug monitoring

Therapeutic drug monitoring for colistin

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age over 18 years old. * Those who receive colistin therapy for the treatment of multi-drug resistant gram negative bacteria infection.

Exclusion criteria

* Those who received colistin therapy less than 48 hours * Those who received colistin therapy through the bronchus

Design outcomes

Primary

Measure	Time frame	Description
AKI	Through study completion, an average of 1 month	Emergence rate of acute kidney injury

Secondary

Measure	Time frame	Description
Death	Through study completion, an average of 1 month	Death rate
Negative conversion rate	Through study completion, an average of 1 month	Culture-negative conversion rate Treatment success Treatment success

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026